Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2024年3月9日 - 6:02AM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
company developing transformational treatments for patients with
serious metabolic disease marked by high unmet medical
need, announced today the closing of its previously announced
underwritten public offering of 12,650,000 shares of its common
stock at a public offering price of $29.00 per share,
which includes the exercise in full by the underwriters of their
option to purchase up to an additional 1,650,000 shares of common
stock in this offering. The gross proceeds from the offering,
before deducting underwriting discounts and commissions and
estimated offering expenses, were approximately $366.9 million.
J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI acted as
joint book-running managers for the offering.
The shares of common stock were offered by Akero pursuant to an
automatically effective shelf registration statement that was
previously filed with the U.S. Securities and Exchange Commission
(SEC). A final prospectus supplement and accompanying prospectus
relating to and describing the terms of the offering was filed with
the SEC on March 6, 2024. The final prospectus supplement and
accompanying prospectus relating to the offering may be obtained
from: J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by
telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014, or by email at prospectus@morganstanley.com;
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY 10022, by telephone at (877)
821-7388, or by email at prospectus_department@jefferies.com; or
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 35th Floor, New York, NY 10055, by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com; or by
accessing the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing
transformational treatments for patients with serious metabolic
diseases marked by high unmet medical need, including metabolic
dysfunction-associated steatohepatitis (MASH), a disease without
any approved therapies. Akero’s lead product candidate,
efruxifermin (EFX), is currently being evaluated in two ongoing
Phase 3 clinical trials: the SYNCHRONY Histology study in patients
with pre-cirrhotic MASH (F2-F3 fibrosis) and the SYNCHRONY
Real-World study in patients with MASH or MASLD. A third clinical
trial, the SYNCHRONY Outcomes study in patients with cirrhosis due
to MASH, is expected to be initiated in the first half of 2024. The
Phase 3 SYNCHRONY program builds on the results of two Phase 2b
clinical trials, the HARMONY study in patients with pre-cirrhotic
MASH and the SYMMETRY study in patients with cirrhosis due to
MASH.
Investor Contact:Christina
Tartaglia212.362.1200IR@akerotx.com
Media Contact:Sarah
O’Connell732.456.0092soconnell@vergescientific.com
Akero Therapeutics (NASDAQ:AKRO)
過去 株価チャート
から 4 2024 まで 5 2024
Akero Therapeutics (NASDAQ:AKRO)
過去 株価チャート
から 5 2023 まで 5 2024